Pharmosa Biopharm (ROCO:6875) Operating Margin %: -276.33% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6875 Pharmosa Biopharm Inc ROCO:6875
11 GF Score
Price NT$35.55
! 1 Warning Sign
View Full Analysis

What is Pharmosa Biopharm Operating Margin %?

Pharmosa Biopharm ROCO:6875 +0.14% 11 Operating Margin % is -276.33% as of Dec. 2025. GuruFocus rates ROCO:6875 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 939 Biotechnology companies, Pharmosa Biopharm ranks worse than 72.42% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Pharmosa Biopharm's Operating Income for the three months ended in Dec. 2025 was NT$-131.52 Mil. Pharmosa Biopharm's Revenue for the three months ended in Dec. 2025 was NT$47.59 Mil. Therefore, Pharmosa Biopharm's Operating Margin % for the quarter that ended in Dec. 2025 was -276.33%.

The historical rank and industry rank for Pharmosa Biopharm's Operating Margin % or its related term are showing as below:

ROCO:6875' s Operating Margin % Range Over the Past 10 Years
Min: -598.88   Med: -130.43   Max: -0.9
Current: -598.88


ROCO:6875's Operating Margin % is ranked worse than
72.42% of 939 companies
in the Biotechnology industry
Industry Median: -86.33 vs ROCO:6875: -598.88

Pharmosa Biopharm's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Pharmosa Biopharm's Operating Income for the three months ended in Dec. 2025 was NT$-131.52 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-402.86 Mil.


Pharmosa Biopharm  (ROCO:6875) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Pharmosa Biopharm Operating Margin % Related Terms


Pharmosa Biopharm Operating Margin % Historical Data

* Premium members only.

The historical data trend for Pharmosa Biopharm's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmosa Biopharm Operating Margin % Chart

Pharmosa Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial 0.00 0.00 -0.90 -130.43 -598.88

Pharmosa Biopharm Quarterly Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.18 0.00 -577.95 -1,754.90 -276.33

ROCO:6875 vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Pharmosa Biopharm's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmosa Biopharm Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmosa Biopharm's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Pharmosa Biopharm's Operating Margin % falls into.


ROCO:6875
11GF Score
Pharmosa Biopharm Inc ROCO:6875
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmosa Biopharm Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Pharmosa Biopharm's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-402.855 / 67.268
=-598.88 %

Pharmosa Biopharm's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-131.517 / 47.594
=-276.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -276.33% mean?
Pharmosa Biopharm (ROCO:6875) has a Operating Margin % of -276.33% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Pharmosa Biopharm and its competitors. According to the industry distribution chart, Pharmosa Biopharm ranks #680 out of 939 companies in the Biotechnology industry, placing it in the top 72.4%.
Is Pharmosa Biopharm's Operating Margin % too high?
Pharmosa Biopharm's current Operating Margin % is -276.33%. Based on the distribution chart, Pharmosa Biopharm ranks #680 out of 939 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pharmosa Biopharm has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Pharmosa Biopharm's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmosa Biopharm ranks #680 out of 939 companies for Operating Margin %. This places Pharmosa Biopharm in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Pharmosa Biopharm and its competitors. Pharmosa Biopharm's current Operating Margin % is -276.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmosa Biopharm stock overvalued right now?
Pharmosa Biopharm (ROCO:6875) has a current Operating Margin % of -276.33%. The current Operating Margin % is -276.33%. Pharmosa Biopharm's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Pharmosa Biopharm (ROCO:6875), the current Operating Margin % is -276.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmosa Biopharm Business Description

Address No. 508, Sec. 7, Zhongxiao E. Road, 11th Floor / 11th Floor-1, Nangang District, Taipei, TWN
Pharmosa Biopharm Inc is a world-class biotechnology company. The Company's principal business activities comprise the development and commercialization of inventive biopharmaceutical drugs. Its product portfolio includes sustained-release dosage forms and drug-device combination products intended for home based therapies.
11GF Score

Get the complete analysis for ROCO:6875

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$35.55
Price